Anti-HER2 monoclonal antibody based-radioimmunoconjugates
Carregando...
Data
2021
Data de publicação:
Orientador
Título da Revista
ISSN da Revista
Título do Volume
É parte de
É parte de
É parte de
Bioorganic & Medicinal Chemistry
Resumo
In the present work, the radioimmunoconjugates 111In-DTPA-trastuzumab and 177Lu-DOTA-trastuzumab were
evaluated regarding the influence of the chelating agents on the physical–chemical parameters and human
epidermal growth factor receptor 2 (HER2) tumor cell binding. Data showed that both chelating agents, at
predetermined molar ratios (antibody:chelator 1:10 and 1:20), did not influence the immunoconjugates
integrity, the radiolabeling process and the radiolabeled antibodies stability. However, differences were observed
in the lipophilic feature between DOTA and DTPA radioimmunoconjugates and in the specific binding to SK-BR-3
tumor cells (HER2 positive). Therefore, this study showed the importance of assessing the influence of chelating
agents and their molar ratios in the development process of radioimmunoconjugates.
Como referenciar
MIRANDA, ANA C.C.; DURANTE, ANA C.R.; FUSCALDI, LEONARDO L.; BARBEZAN, ANGELICA B.; LIMA, CILENE R. de; PERINI, EFRAIN; ARAUJO, ELAINE B. de. Anti-HER2 monoclonal antibody based-radioimmunoconjugates: assessment of the chelating agent influence. Bioorganic & Medicinal Chemistry, v. 33, p. 1-9, 2021. DOI: 10.1016/j.bmc.2021.115996. Disponível em: http://repositorio.ipen.br/handle/123456789/31971. Acesso em: 28 Mar 2024.
Esta referência é gerada automaticamente de acordo com as normas do estilo IPEN/SP (ABNT NBR 6023) e recomenda-se uma verificação final e ajustes caso necessário.